German watchdog calls for direct comparison of cancer immunotherapies [Reuters]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Reuters
German watchdog calls for direct comparison of cancer immunotherapies | Reuters Reuters Staff 3 Min Read FRANKFURT, Jan 15 (Reuters) - Germany’s drug assessment body has criticised a lack of data directly comparing drugs in a promising new class of cancer immunotherapy, saying physicians could be overwhelmed or misled by the available information. IQWiG, the independent authority in Germany that evaluates new drugs and plays a key role in what price health services pay for them, has looked into new immunotherapy drugs for the treatment of bladder cancer as part of its so-called early benefit assessment. It concluded there were some signs that patients who could not be helped by previous courses of standard chemotherapy could benefit considerably from Merck & Co’s Keytruda and Roche’s Tecentriq, but said physicians needed head-to-head drug trials to pick the best treatment option. “The procedure of the early benefit assessment does unfortunately not allow a comparison of new drugs agai
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025 [Yahoo! Finance]Yahoo! Finance
- Merck's Future Brightens With Winrevair's Blockbuster Potential [Seeking Alpha]Seeking Alpha
- Algernon Pharmaceuticals Announces Closing of the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position [Financial Post (Toronto, Ontario, Canada)]Financial Post
- Algernon Pharmaceuticals Announces Closing of the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position [Yahoo! Finance]Yahoo! Finance
- Merck Drug for Rare Form of High Blood Pressure Gets US Nod [Yahoo! Finance]Yahoo! Finance
MRK
Earnings
- 2/1/24 - Beat
MRK
Sec Filings
- 3/19/24 - Form S-3ASR
- 3/19/24 - Form S-3ASR
- 2/26/24 - Form 10-K
- MRK's page on the SEC website